Cargando…

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

SIMPLE SUMMARY: Pembrolizumab, an immune checkpoint inhibitor, has shown therapeutic benefit for advanced urothelial carcinoma (aUC) patients, but only a limited population achieves a long-term response. Prediction of treatment outcomes for aUC patients receiving immune checkpoint inhibitors is a cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakatani, Toru, Kita, Yuki, Fujimoto, Masakazu, Sano, Takeshi, Hamada, Akihiro, Nakamura, Kenji, Takada, Hideaki, Goto, Takayuki, Sawada, Atsuro, Akamatsu, Shusuke, Kobayashi, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774131/ https://www.ncbi.nlm.nih.gov/pubmed/35053427 http://dx.doi.org/10.3390/cancers14020263

Ejemplares similares

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Paraurachal paraganglioma
por: Tsuruta, Masafumi, et al.
Publicado: (2022)

Incomplete sagittal septum of the bladder with cystolithiasis
por: Fujimoto, Takeru, et al.
Publicado: (2022)

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
por: Shimizu, Kosuke, et al.
Publicado: (2022)

Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture
por: Hagimoto, Hiroki, et al.
Publicado: (2022)

Robot-assisted partial nephrectomy for renal cell carcinoma in the isthmus of horseshoe kidney
por: Sawada, Atsuro, et al.
Publicado: (2022)

A 45,X/46,XY Male with Orchidopexy Diagnosed with Mixed Germ Cell Tumor After 21-year Follow-up
por: Kubota, Masashi, et al.
Publicado: (2017)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

The Roles of Extracellular Vesicles in the Progression of Renal Cell Carcinoma and Their Potential for Future Clinical Application
por: Takeda, Masashi, et al.
Publicado: (2023)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens‐like epithelium
por: Takamori, Hajime, et al.
Publicado: (2020)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse model
por: Takeda, Masashi, et al.
Publicado: (2023)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

Urothelial Tumor
Publicado: (2016)

Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma
por: Yoshimura, Akihiro, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report
por: Tohi, Yoichiro, et al.
Publicado: (2019)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab
por: Alnajar, Hussein, et al.
Publicado: (2022)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer
por: Mandelli, Giulio Eugenio, et al.
Publicado: (2020)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment
por: Goto, Keisuke, et al.
Publicado: (2021)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lugia0h5kllf53cqm4a1lv9aab